EN PL
REVIEW PAPER
Rituximab: the role in the treatment of rheumatoid arthritis
 
More details
Hide details
 
Online publication date: 2011-03-16
 
 
Reumatologia 2011;49(1):55-61
 
KEYWORDS
ABSTRACT
Rituximab is an antibody directed against B cells involved in the inflammatory processes in the course of autoimmune diseases. It is recommended in rheumatoid arthritis (RA) patients with persistent active inflammation despite treatment with classical disease-modifying antirheumatic drugs (DMARDs) and anti-TNF- α agents. In this particular population, its efficacy is higher than that of anti-TNF-α drugs. Rituximab may be used for many years maintaining the same level of efficacy. The most common adverse events are those experienced at the time of drug administration by infusion and are mainly associated with the release of cytokines from B cells. The frequency and intensity of those drug reactions decrease significantly upon premedication with glucocorticosteroids and with each subsequent drug dose. Another type of complications is infections, although their incidence is no higher than in the total population of RA patients. Practical aspects of qualification of patients for treatment as well as the procedure of infusion preparation and administration are also presented.
REFERENCES (22)
1.
Filipowicz-Sosnowska A. Reumatoidalne zapalenie stawów. W: Reumatologia kliniczna. Zimmerman-Górska I (red.). Wydawnictwo Lekarskie PZWL, Warszawa 2008; 495.  .
 
2.
Frampton J, Scott L. Rituximab in rheumatoid arthritis. Biodrugs 2007; 21: 333-341.  .
 
3.
Sibilia J, Rottenberg JE, Mariette X. Rituximab: A new therapeutic alternative in rheumatoid arthritis. Joint Bone Spine 2008; doi: 10.1016/j.jbspin.2008.02.009.  .
 
4.
Dass S, Vital E, Emery P. Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis. Expert Opin Pharmacother 2006; 7: 2559-2570.  .
 
5.
Charakterystyka Produktu leczniczego Mabthera®.  .
 
6.
Charakterystyka produktu leczniczego. Roche Registration Limited, 6 Falcon Way, Sire Park, Welvyn Garden City, AL7 1TW, Wielka Brytania.  .
 
7.
Edwards J, Szczepański L, Szechiński J. Efficacy of B-cell-targeted therapy with rituksimab In patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-2581.  .
 
8.
Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotreksate treatment. Arthritis Rheum 2006; 54: 1390-1400.  .
 
9.
Cohen S. Continued Inhibition of Structal Damage in Rheumatoid Arthritis Patients Treated with Rituximab at 2 years: REFLEX study. Arthritis Rheum 2008; 58: (suppl): S303. .
 
10.
Cohen. S, Emery P, Greenwald M, et al. Rituxymab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 2006; 54: 2793-2806. .
 
11.
Keystone E, Emery P, Peterfy C, et al. Rituximab inhibits structural join damage in patients with rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitor therapies. Ann Rheum Dis 2009; 68: 216-221. .
 
12.
Keyston E, Burmester G, Furie R, et al. Improvement in patients-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 2008; 59: 785-793. .
 
13.
Keyston E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis. Arthritis Rheum 2007; 56: 3896-3908. .
 
14.
Mease P, Cohen S, Gaylis N, et al. Efficacy, safety, and dose frequency of retreatment with rituximab in RA: results from a randomized controlled trial (SUNRISE). Arthritis Rheum 2008; 58: S619. .
 
15.
Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of rheumatoid arthritis patients benefis from switching to ritu­ks­imab versus alternative anti-TNF agents after previous failure to anti-TNF agent? Ann Rheum Dis online 04 May 2009, doi: 10.1136/ard.2008.105064. .
 
16.
Gomez-Reino JJ, et al. Rituximab compared with further tumour necrosis factor (TNF) antagonist therapy in rheumatoid arthritis (RA) patients who had previously failed TNF antagonist therapy: Results of a prospective, observational study. Ann Rheum Dis 2009; 68 (Suppl 3): 442. .
 
17.
Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trias. Ann Rheum Dis 2009; 68: 25-32. .
 
18.
van Vollenhoven RF, et al. Long-Term Safety of Rituximab: Long-Term Follow-up of the RA Clinical Trials and Retreatment Population. Arthritis Rheum 2009; 60 (10 Suppl): S730. .
 
19.
Genovese MC, Breedveld F, Emery P, et al. Safety of biologic therapies following rituximab treatment in rheumatoid arthritis patients. Ann Rheum Dis 2009; doi:10.1136/ard.2008. 101675. .
 
20.
Szechiński J, Głuszko P, Kucharz E i wsp. Konsensus dotyczący stosowaniu rituksymabu w leczeniu chorych na reumatoidalne zapalenie stawów. Reumatologia 2007; 45: 115-119. .
 
21.
Smolen J, Keystone E, Emery P, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 143-150. .
 
22.
Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatoid diseases, 2007. Ann Rheum Dis 2007; 66: 2-22.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top